Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA with Any PARP Inhibitor for Cancer Treatment

Regulatory News:

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO), granting the Company a new patent covering the combination of AsiDNA, Onxeo’s first-in-class DDR inhibitor, with any PARP inhibitor (PARPi) for cancer treatment, in the United States.

Onxeo was granted a corresponding patent in Europe in December 2018. The new U.S. patent, is valid until 2036. It further expands Onxeo’s intellectual property portfolio for AsiDNA, which now includes 168 number of patents globally.

"Cancer therapeutic resistance is one of the most significant challenges for successful treatment. Therefore, fighting acquired resistance has become a key focus for researchers and clinicians around the world. Our translational studies of AsiDNA have demonstrated its significant potential in combating cancer therapeutic resistance to both DNA-damaging agents and targeted therapies such as PARPi. This new patent, which expands the protection of the combination of AsiDNA with any PARP inhibitor to the leading U.S. market, further supports the initiation of a new clinical study in the coming months that is designed to validate this very unique effect of AsiDNA on the acquired resistance to a PARPi," said Judith Greciet, Chief Executive Officer of Onxeo.

Onxeo has conducted an extensive preclinical program with AsiDNA in combination with various PARPi in several cancer models, such as triple negative breast cancer and small-cell lung cancer. In addition to demonstrating the strong synergistic effect of the combination, even in cancer cells non-sensitive to PARPi alone, the translational studies have shown the ability of AsiDNA to prevent the onset of tumor resistance to PARPi and even abrogate an acquired resistance. This property will be further evaluated in the upcoming Phase 1b clinical study of AsiDNA in combination with a PARP inhibitor in advanced ovary cancer.